isis 333611
Nucleic acidexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01041222)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Superoxide dismutaseANTISENSE INHIBITOR
SOD1 antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- isis 333611
- isis 333611
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01041222 | Phase 1 | Jan 1, 2010 | ALS Association, Harvard University, Ionis Pharmaceuticals, Inc., Muscular Dystrophy Association, Washington University in St. Louis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ALS Association | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Ionis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2010 |
| Muscular Dystrophy Association | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1